Joshua Yang
Pediatric Endocrinology · Orlando, FLNPI 1588677876
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $599,020 of the $845,809 with a category attached, or 70.8%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.3%. 2025 is the largest year on record at $397,851, more than ten times the $17,938 reported in 2019. Among pediatric endocrinology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,400 payments — averaging $604.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$180K
- Kyowa Kirin, Inc.$176K
- Sanofi-aventis U.S. LLC$172K
- AbbVie$111K
- Novo Nordisk$76K
- Tolmar, Inc.$46K
- plus $85K from 22 others
Across 91 payments — averaging $2450.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$111K
- AbbVie$83K
- Pfizer$14K
- Novo Nordisk Health Care AG$14K
What the payments were for
- Consulting fees$80,97610%
- Speaking & faculty fees$599,02071%
- Travel & lodging$132,82716%
- Food & beverage$32,3824%
- Education$6040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 343 | $180,135 |
| Kyowa Kirin, Inc. | 293 | $176,402 |
| Sanofi-aventis U.S. LLC | 128 | $171,919 |
| AbbVie | 147 | $110,757 |
| Novo Nordisk | 106 | $75,800 |
| Tolmar, Inc. | 73 | $45,831 |
| AstraZeneca | 72 | $33,434 |
| Azurity Pharmaceuticals, Inc. | 21 | $16,873 |
| Sanofi US Services Inc. | 1 | $10,273 |
| Tolmar Pharmaceuticals, Inc. | 15 | $7,923 |
| Sanofi | 2 | $4,218 |
| Ferring Pharmaceuticals Inc. | 10 | $3,569 |
| Insulet Corporation | 117 | $2,622 |
| Pfizer | 7 | $2,106 |
| Tandem Diabetes Care, Inc. | 14 | $820 |
| BETA Bionics, Inc. | 8 | $590 |
| Eton Pharmaceuticals, Inc. | 2 | $537 |
| Dexcom, Inc. | 8 | $452 |
| Abbott | 2 | $260 |
| Xeris Pharmaceuticals, Inc. | 3 | $257 |
| Medtronic | 5 | $246 |
| Neurocrine Biosciences, Inc. | 6 | $157 |
| Biomarin Pharmaceutical Inc. | 4 | $148 |
| Ultragenyx Pharmaceutical Inc. | 2 | $132 |
| Amgen | 1 | $125 |
| Lilly USA, LLC | 3 | $100 |
| Endo USA, Inc. | 3 | $63 |
| Endo Pharmaceuticals Inc. | 4 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$167,614
- SKYTROFA$152,954
- Lupron Depot$101,608
- CRYSVITA$88,307
- Sogroya$66,895
- FENSOLVI$52,147
- Strensiq$19,540
- Triptodur$7,658
- Norditropin$7,615
- ZOMACTON$3,247
- iLet Bionic Pancreas$1,366
- Omnipod$1,001
- GALZIN$519
- CARGLUMIC ACID$519
- BETAINE ANHYDROUS$519
- NITISINONE$519
- GVOKE PFS$237
- t:slim X2 Insulin Pump with Control-IQ$212
- FreeStyle Libre$160
- DEXCOM G6 TRANSMITTER$130
How this compares
$845,809 in reported general payments places this provider in the 95th percentile of 102 pediatric endocrinology providers in Florida.
Other pediatric endocrinology in Orlando
- Matthew BensonOrlando$32K
- Neha VyasOrlando$6K
- Erin GreenupOrlando$6K
- Jennifer VillarOrlando$3K
- Michelle Rivera-VegaOrlando$3K
- Penelope PauleyOrlando$3K
- Paul DesrosiersOrlando$3K
- Richard BanksOrlando$2K
- Katherine VelezOrlando$2K
- Shadi TabbaOrlando$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.